Nanobiohybrids and Bacterial Carriers: A Novel Pathway to Targeted Cancer Therapy

Abstract
Recent advances in nanotechnology and biotechnology, a testament to our collective efforts, have allowed new perspectives to develop for therapies against cancer. The bacterial carriers within the nanobiohybrids, a product of our collaborative research, represent a new way of precision medicine that will take targeting and efficacy of cancer treatments to other levels. This research, a joint endeavor, will examine the potentials of bacteriomimetics, where bacteria act as nanocarriers for targeted drug delivery using their natural pathotropism in effective colonization into tumor sites, even to hypoxic areas that are hard to treat with the use of conventional methods. Engineered surfaces of bacteria, a result of our shared knowledge, are designed to improve selective binding and direct therapeutic action at the site of the tumor microenvironment in such a way as not to elicit systemic side effects. This will make a lot of sense for significant development in targeted therapies, where synthetic nanoparticles, incorporated with bacterial systems in these nanobiohybrids, ensure enhanced drug stability with controlled release. The potential of such systems to deliver chemotherapeutic agents and produce localized, real-time therapeutic responses exemplifies a leap toward personalized cancer treatment. This approach not only offers the promise of more refined therapeutic outcomes but is further aimed at reducing the unwanted effects that do quite often appear while undergoing many cancer treatments. This means that future research, a shared commitment, will focus on optimizing these biohybrid systems for their clinical application, promising a new horizon in oncological care.

Author
Diyar Salahuddin Ali, Sarhang Hayyas Mohammed

DOI
https://doi.org/10.1088/2399-1984/ad7802

ISSN

Publish Date: 2024-09-06